A pan-tumor study of three independent cohorts of over 500 patients with advanced cancer treated with anti-PD-1 or anti-PD-L1 antibodies revealed that the presence of mature TLSs, identified using immunohistochemical co-staining for CD3, CD20, and CD23, predicted immunotherapy efficacy and improved progression-free and overall survival regardless of PD-L1 expression (144). This evidence concerns the gene CD274 and cancer.